Clinical Trials · NCT07429045
A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Amgen
- Enrollment
- 44
- Start date
- Mar 2025
- Locations
- 5 sites, United States
- Primary endpoint
- Maximum Observed Concentration (Cmax) of AMG 133